Contributions
Abstract: P589
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Biomarkers
Background and objective: Several studies found the T-cell activation marker soluble CD27 (sCD27) increased in various autoimmune diseases including multiple sclerosis (MS). The objective of this study was to investigate whether CSF sCD27 levels, in patients with clinically isolated syndrome (CIS), predict a subsequent diagnosis of MS and are associated with a higher relapse rate.
Methods: In this prospective study sCD27 levels were determined in CSF of 77 CIS patients using a commercially available ELISA. CIS patients underwent a lumbar puncture and MRI scan within 6 months after first onset of symptoms. Cox regression analysis was used to calculate univariate and multivariate hazard ratios (HR) for MS diagnosis. Association between sCD27 levels and annualized relapse rate (ARR) was assessed using a negative binomial regression model.
Results: CIS patients had higher sCD27 levels in CSF than symptomatic controls (SCs). The geometric mean (95% CI) was 31.3 u/mL (24.0-40.9) vs 4.67 u/mL (2.90-7.50) (p< 0.01). During a mean follow-up of 52.4 months, 39 out of 77 CIS patients were diagnosed with MS. In a model adjusted for MRI measurements, IgG index, and oligoclonal bands, sCD27 levels were associated with a diagnosis of MS (HR for MS diagnosis: 2.2 per 100 units/mL increase in sCD27 levels (p=0.02)). Additionally MS patients with high sCD27 levels (>31.4 units/mL(median)) at time of CIS had a 5.7 times higher ARR than patients with low sCD27 levels (p=0.02).
Conclusions: Soluble CD27, measured in CSF of CIS patients, predicts MS diagnosis and a high relapse rate. Therefore sCD27 is an activation marker directly related to the immunopathology of the disease and could be a valuable biomarker for selecting patients with higher disease activity.
Disclosure:
RM van der Vuurst de Vries: nothing to disclose
JY Mescheriakova: nothing to disclose
TF Runia: nothing to disclose
N Jafari: nothing to disclose
DAM Siepman: nothing to disclose
RQ Hintzen: nothing to disclose
Abstract: P589
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Biomarkers
Background and objective: Several studies found the T-cell activation marker soluble CD27 (sCD27) increased in various autoimmune diseases including multiple sclerosis (MS). The objective of this study was to investigate whether CSF sCD27 levels, in patients with clinically isolated syndrome (CIS), predict a subsequent diagnosis of MS and are associated with a higher relapse rate.
Methods: In this prospective study sCD27 levels were determined in CSF of 77 CIS patients using a commercially available ELISA. CIS patients underwent a lumbar puncture and MRI scan within 6 months after first onset of symptoms. Cox regression analysis was used to calculate univariate and multivariate hazard ratios (HR) for MS diagnosis. Association between sCD27 levels and annualized relapse rate (ARR) was assessed using a negative binomial regression model.
Results: CIS patients had higher sCD27 levels in CSF than symptomatic controls (SCs). The geometric mean (95% CI) was 31.3 u/mL (24.0-40.9) vs 4.67 u/mL (2.90-7.50) (p< 0.01). During a mean follow-up of 52.4 months, 39 out of 77 CIS patients were diagnosed with MS. In a model adjusted for MRI measurements, IgG index, and oligoclonal bands, sCD27 levels were associated with a diagnosis of MS (HR for MS diagnosis: 2.2 per 100 units/mL increase in sCD27 levels (p=0.02)). Additionally MS patients with high sCD27 levels (>31.4 units/mL(median)) at time of CIS had a 5.7 times higher ARR than patients with low sCD27 levels (p=0.02).
Conclusions: Soluble CD27, measured in CSF of CIS patients, predicts MS diagnosis and a high relapse rate. Therefore sCD27 is an activation marker directly related to the immunopathology of the disease and could be a valuable biomarker for selecting patients with higher disease activity.
Disclosure:
RM van der Vuurst de Vries: nothing to disclose
JY Mescheriakova: nothing to disclose
TF Runia: nothing to disclose
N Jafari: nothing to disclose
DAM Siepman: nothing to disclose
RQ Hintzen: nothing to disclose